Abstract: An object of the present invention is to provide an adjuvant for a mucosal vaccine with high safety that induces a sufficient immune response on the mucosa. According to the present invention, an adjuvant for a mucosal vaccine comprising a protein complex composed of hemagglutinin (HA) subcomponents HA1, HA2, and HA3 of botulinum toxin is provided.

Abstract: The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses of a DLL4 antagonist.

Abstract: The present invention provides compositions and methods for the treatment of sarcoma. The compositions comprise an antibody that binds at least one of IGF-1 and IGF-2 and an mTOR inhibitor. The mTOR inhibitor may be AZD2014 or rapamycin.

Abstract: The present invention provides combination therapies that employ a GITR binding molecule in combination with one or more additional agents.

Abstract: This document provides methods and materials related to treating cancer (e.g., skin cancer). For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE®/anti-VEGF polypeptide antibody complexes) to treat cancer (e.g., skin cancer) are provided.

Abstract: Antibody variants originating from the monoclonal antibody 13C6, and wherein the N-glycosylation site within the constant region of the heavy chain contains a glycan that is either wild-type or largely devoid of fucose residues, will bind Ebola virus glycoprotein and provide surprising efficacy in treating animals or humans infected with Ebola virus when used in combination with one or more additional anti-Ebola mAbs. Such antibody cocktails are vastly superior to other known monoclonal antibodies or monoclonal antibody combinations in treating animals and humans infected with the Ebola virus.

Abstract: Near infrared radiation at a wavelength that induces resonance in water is used to remotely activate thermal plasticization of polymeric particles to trigger the release of encapsulated molecules from the particles. Nanocarriers formed from biocompatible hydrophilic polymers may be used to deliver encapsulated molecules to tissue with a reversible transition that allows repeated activations for extended release of the payload.

Abstract: The present invention is directed to the provision of multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP). The compositions include at two different polyols in conjunction with borate and a low concentration of benzalkonium chloride.

Abstract: The present invention is directed to stable linaclotide compositions and methods of treating gastrointestinal disorders in patients in need thereof by providing the stable linaclotide compositions.

Abstract: The present disclosure relates to methods, compositions, and devices for treatments related to mammary tissue in subjects, including reducing the incidence of mastitis. In particular, the disclosure can relate to creating a physical barrier on a teat surface, in a teat canal, or in a teat cistern for prophylactic treatment of mammary disorders.

Abstract: The invention generally relates to synthetic mimics of cell penetrating peptides. More particularly, the invention relates to certain novel monomers, oligomers and polymers (e.g., co-polymers) that are useful for the preparation of synthetic mimics of cell penetrating peptides, their compositions, preparations and use.

Abstract: The present invention relates to new formulations, particularly useful in the topical treatment of skin and oromucosal wounds. Formulations can be either a solution or a gel form consisting of a Polyhexamethylene biguanide as an antimicrobial agent, purified water and a tri-blockcopolymer, particularly a triblockcopolymer of polyethylene oxide and polypropylene oxide, and more particularly a poloxamer.

Abstract: The present invention provides conjugates and methods of using the same for the treatment of cerebral, meningeal, and neural diseases, disorders, and conditions. Provided methods include administering conjugates directly into the cerebrospinal fluid space of an animal.

Abstract: The present invention provides among other things a composition of a polymeric reagent and an antioxidant, such as butylated hydroxyl toluene.

Abstract: Pharmaceutical compositions of conjugates are provided. The conjugates can be prepared by (among other ways) conjugating a pharmacologically active agent with a polymeric reagent that has a particular arrangement of atoms. Related methods, preparations, and so forth are also provided.

Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.

Abstract: Provided are transmembrane complexes that contain a protein transduction domain (PTD) from the N-terminus of IgE-dependent histamine-releasing factor (HRF) and a target substance that is to be delivered into a cell. Also provided are nucleic acid molecules encoding the transmembrane complex and methods of delivering the target substance into a cell interior by contacting the transmembrane complex with a cell. Also provided are transfection kits containing the PTD and the target substance.

Abstract: Peptide dendrimers and agents are described, which can be used for polymerising fibrinogen and as haemostatic agents. The peptide dendrimers comprise a branched core, and a plurality of fibrinogen-binding peptides separately covalently attached to the branched core.

Abstract: The present invention discloses a hypericin albumin nanoparticle-Escherichia coli serum antibody complex, which is obtained through adding mixed hypericin albumin nanoparticles and rabbit anti-Escherichia colis into ethanediol, irradiating them with carbon ion, setting them at a low temperature for 2 hours after irradiation, centrifuging them at a low temperature, and freezing and drying the precipitates. Its preparation method and application are also provided.

Abstract: The present invention relates to a method for purifying a mixture of cysteine-linked antibody-drug conjugates, wherein the amount of non-conjugated antibody is in the range of 0-40% by weight, using hydrophobic interaction chromatography (HIC). The mixture is loaded onto a preparative HIC column using a 0.2-1.5 M aqueous salt solution, in which non-conjugated antibody is collected in a flow-through fraction, followed by elution of a purified mixture of cysteine-linked antibody-drug conjugates using a 0-100 mM aqueous salt solution.

Abstract: The present invention is directed to methods of preparing a conjugate of a cell-binding agent and a drug (such as a cytotoxic compound). The methods comprise the use of an imine reactive compound to enable efficient conjugations of cytotoxic compounds with cell binding agents.

Abstract: Disclosed herein are antibody drug conjugates having an antibody or antibody fragment that binds a cell surface molecule on a target cell, wherein the target cell is a lymphocyte and a therapeutic agent that has a therapeutic effect in a subject in need thereof. Further disclosed herein are antibody drug conjugates having an antibody or antibody fragment that binds a cell surface molecule on a target cell; and a therapeutic agent that binds an intracellular moiety of the target cell. These antibody drug conjugates may be used for treating cardiovascular diseases.

Abstract: Disclosed herein are non-myeloablative antibody-toxin conjugates and compositions that target cell surface markers, such as the CD34, CD45 or CD117 receptors, and related methods of their use to effectively conditioning a subject's tissues (e.g., bone marrow tissue) prior to engraftment or transplant. The compositions and methods disclosed herein may be used to condition a subject's tissues in advance of, for example, hematopoietic stem cell transplant and advantageously such compositions and methods do not cause the toxicities that are commonly associated with traditional conditioning methods.

Abstract: Provided are compounds for targeted immunotherapy. The compounds are useful in the treatment of diseases such as cancer. Also provided are compositions comprising the compounds.

Abstract: Herein is reported a bispecific antibody comprising a first binding specificity that specifically binds to a haptenylated payload and a second binding specificity that specifically binds to a blood brain barrier receptor.

Abstract: Open three-dimensional network, microporous hydrogels containing substrates attached to binding molecules is disclosed. The hydrogel is comprised of a hydrated gel matrix containing substrates embedded in the matrix. The substrates are attached to binding molecules that selectively bind specific molecules that encounter the hydrogel. Thus the hydrogel serves to selectively bind out target molecules from an aqueous environment or sample that the hydrogel comes in contact with and concentrates them within the hydrogel.

Abstract: This invention provides liposomes for delivering to target cells in a subject, nucleic acids for expressing telomerase reverse transcriptase and/or telomerase RNA component. Expression of active telomerase can extend the length of telomeres in the cell. Such lengthening can be useful in subjects suffering from diseases associated with shortened telomeres.

Abstract: Described herein are methods and compositions for genomic editing. Clustered regularly interspaced short palindromic (CRISPR) allows for highly selective targeting and alteration of genetic loci. Here, the Inventors demonstrate CRISPR as capable of being used in living animals to prophylactically prevent a genetic disease from manifesting. Targeting and disruption of mutated rhodopsin gene prevents progression of retinitis pigmentosa in the retinal cells of a transgenic rat model. Such techniques allow for treatment methods in subjects with dominant genetic mutations, often associated with lack of a gene product, or a toxic gene product. The described technology effectively abrogates deleterious effects due to the presence of a mutated gene copy allowing the normal function of the wild-type protein to prevent cell and vision loss. The efficacy of these in vivo mechanisms are widely extensible to similar dominant negative gene mutations causing disease, or other types of genetic disease.

Abstract: The present invention provides methods and materials useful delivering liquids, including liquids comprising nucleic acid molecules into cells. In particular, the present invention provides methods for delivering saline solution, exogenous compositions, and isolated vectors to kidney cells, using the renal vein as a guide and under hydrodynamic pressure. The delivery methods and materials herein are useful to research, prognose, ameliorate symptoms of kidney injury, and treat kidney pathologies.

Abstract: A method of increasing blood-brain barrier permeability of selected brain tissue in a subject in need thereof is carried out by: (a) parenterally administering to the subject stem cells that migrate to the brain tissue, the stem cells containing a recombinant nucleic acid, the recombinant nucleic acid comprising a nucleic acid encoding a barrier-opening protein or peptide operably associated with a heat-inducible promoter; and then (b) selectively heating the selected brain tissue sufficient to induce the expression of the barrier-opening protein or peptide in an amount effective to increase the permeability of the blood-brain barrier in the selected brain tissue. Nucleic acids, vectors, stem cells and compositions useful for carrying out such methods are also described.

Abstract: An imaging agent for detecting analytes in an environment includes functionalized nanodiamonds and functionalized magnetic particles that can selectively interact with an analyte. Each functionalized nanodiamond contains at least one color center configured emit light in response to illumination. At least one property of the light emitted by the color centers is related to the proximity of the functionalized magnetic particles to the color centers. This property can be detected to determine that the functionalized nanodiamonds are proximate to the functionalized magnetic particles, to determine that the functionalized nanodiamonds and the functionalized magnetic particles are interacting with the analyte, or other applications. Devices and methods for detecting properties of the analyte by interacting with the functionalized nanodiamonds and functionalized magnetic particles are also provided.

Abstract: Microfabricated platforms can be used to study a heterogeneous panel of biosamples in a realistic in vivo setting. The platform can be formed of a polymer (e.g., a hydrogel) and can be constructed for implantation into an animal host for in vivo testing. The platform can have a plurality of testing regions therein that are constructed to allow exposure of the testing region to the host stroma when implanted in vivo. For example, the microfabricated platform can be used for screening different cancer cell-lines (e.g., to identify which cell line responds to an anti-cancer drug) or for screening different biomaterials (e.g., to identify a composition with ideal host response for a specific implantable device).

Abstract: A method of detecting an atherosclerotic plaque vulnerable to rupture in a subject comprises providing to the subject a labelled necrostatin or a derivative thereof, and visualizing the label, wherein a localization of the label in a plaque indicates the plaque is vulnerable to rupture. A method of detecting and treating an atherosclerotic plaque vulnerable to rupture comprises providing to the subject a labelled necrostatin or a derivative thereof, visualizing the label, wherein a localization of the label in a plaque indicates the plaque is vulnerable to rupture; and providing a necroptosis inhibitor or derivative thereof to the subject when the visualizing indicates that the plaque is vulnerable to rupture. The necroptosis inhibitor may comprise a necrostatin, such as Nec-1. The label may be a radiolabel such as 123I. By visualizing plaques vulnerable to rupture, atherosclerotic plaques may be identified and treated in advance of rupture.

Abstract: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.

Abstract: Provided is a thermal disinfector including a cover, a basin, at least an inlet for water, an outlet to drain the water into the sewer, an outlet for recirculating water so that it can be reintroduced into the basin, at least an ultrasound generator, an electronic control unit, and a water heater positioned outside the basin.

Abstract: A device for transferring a sterile product from one container to another under aseptic conditions. The first container to initially contain the sterile product and equipped with an outlet. The outlet has a first pipe and two independently operable valves mounted in series thereon. The second container is equipped with an inlet having a second pipe and two independently operable valves mounted in series thereon. A removable hose to provide a sealed connection of the free end of the first pipe and the free end of the second pipe. A connector to connect the removable hose to a system for sterilizing the internal volume thereof. The system is operable when the removable hose connects the free end of the first pipe with the free end of the second pipe in a sealed manner.

Abstract: An ultraviolet illuminator for providing a cleaning treatment to a medical device is disclosed. The ultraviolet illuminator can include an ultraviolet cleaning treatment system that operates in conjunction with at least one ultraviolet radiation source and sensor to clean surfaces of a medical device for purposes of disinfection, sterilization, and/or sanitization. The ultraviolet illuminator is suitable for a wide variety of medical devices, instruments and equipment. Stethoscopes and medical instrument probes are illustrative examples of some devices that can be used with the ultraviolet illuminator.

Abstract: Provided is an apparatus for disinfecting objects of various shapes and sizes. The apparatus includes a housing enclosing a disinfecting chamber, and an ultraviolet light source arranged to emit ultraviolet light into the disinfecting chamber to deactivate at least a portion of a biologically-active contagion present on the object. A peripheral wall of the housing that extends about a portion of the disinfecting chamber comprises an ultraviolet-reflective material so that the ultraviolet light impinging on the peripheral wall is reflected generally away from the peripheral wall and toward an interior of the disinfecting chamber. A door is adjustable between open and closed orientations. A floor at the bottom of the disinfecting chamber includes an ultraviolet-reflective surface that reflects the ultraviolet light impinging on the floor generally away from the floor toward the interior of the disinfecting chamber.

Abstract: A fill assembly sterilization system for a blow/fill/seal machine utilizes a closed loop circulation of sterilant containing gas. A typical sterilant is nitrogen dioxide. The closed loop includes a shroud that defines a plenum and encloses the fill system. Optionally, at least one high efficiency particulate absorption (HEPA) filter is provided in the closed loop. Sterility assurance level of 10?6 can be achieved by subjecting the fill system to the sterilizing gas for at least 20 minutes at a temperature in the range of about 18° C. to about 30° C.

Abstract: A perfumed paper roll has a plurality of rings of paper body. Adhesive is between rings of the paper body. The rings of the paper body are impregnated with liquid perfume. A method of manufacturing a perfumed paper roll includes: winding a paper strip by utilizing a rotating machine to form a paper roll having a plurality of rings of paper body; dispensing adhesive between adjacent rings of the paper body during a rotating process; and dripping liquid perfume on the paper roll after removing the paper roll to form the perfumed paper roll.

Abstract: A method and apparatus for vapor dispensing apparatus is described. The vapor dispensing apparatus includes: a housing defining a chamber having an inner contact surface, wherein the housing further comprises an aperture providing fluid communication between the chamber and an external environment; an evaporable material receptacle movably disposed within the chamber such that a dispensing portion of the receptacle is disposed in contact with at least a portion of the surface; and a motor coupled to the apparatus, configured to move the receptacle.

Abstract: A device for dispensing a fragrance includes a container which has at least one outlet opening and is used for receiving the fragrance. Associated to the container is an electric heating element for heating the fragrance and a temperature sensor for detecting the temperature of the fragrance. The electrical heating element is controlled by a controller as a function of the temperature detected by the temperature sensor.

Abstract: An aroma diffuser includes an air pump including an air inlet port and an air outlet port, an aromatherapy nebulizer including a fragrance bottle, an air accumulator, a dip tube, an air outlet tube in communication with the fragrance bottle and an air outlet tube in communication with the air accumulator. When a compressed flow of air is induced by the air pump into the accumulation chamber of the air accumulator, a Venturi effect is created in the outlet of the accumulation chamber, causing the liquid fragrance to be sucked out of the fragrance bottle toward and mixed with the compressed flow of air for diffusion through a spray chamber in the air accumulator and the air outlet tube.

Abstract: The device for diffusing volatile substances comprises means for generating an air stream, and is characterized in that said means for generating an air stream comprise a flexible sheet (1) and at least one piezoelectric element (2), such that said piezoelectric element (2) causes said flexible sheet (1) to expand and shrink to generate the air stream. It allows generating an air flow that is adapted to the geometry of the evaporation surface.

Abstract: System, methods and storage medium associated with generation of hydroxyl and/or reduction of ozone are disclosed. In embodiments, a system may include one or more front end sensors disposed at an input end to measure attributes of an input air stream; an hydroxyl generator/ozone reducer to receive the input air stream and use the input air stream to generate an output air stream with hydroxyl and/or reduced amount of ozone; and one or more back end sensors disposed at an output end to measure attributes of the output air stream. The system may further include a controller to control the hydroxyl generator/ozone reducer based at least in part on readings of the one or more front end sensors and the one or more back end sensors. Other embodiments may be described and/or claimed.

Abstract: A thin nanocomposite film for use in an absorbent article (e.g., sanitary napkin) is provided. The film contains a first ethylene polymer having a density of about 0.94 g/cm3 or less, second ethylene polymer having a density of greater than 0.94 g/cm3, and nanoclay having an organic surface treatment. The present inventors have discovered that through selective control over the particular type and concentration of the components used to form the film, as well as the manner in which it is formed, the properties of the film can be significantly improved.

Abstract: The present invention is related to a patterned membrane comprising nanofibrillar polysaccharides, device and compositions for improving wound healing, as well as to their manufacture and use for therapy.

Abstract: A thin nanocomposite film for use in an absorbent article is provided. The film contains an ethylene polymer, a nanoclay having an organic surface treatment, and a compatibilizer that includes an olefin polymer containing an ethylenically unsaturated carboxylic acid monomer. The present inventors have discovered that through selective control over the particular type and concentration of the components used to form the film, as well as the manner in which it is formed, the modulus and tensile strength of the film can be significantly improved without having an adverse impact on its ductility.

Abstract: The present invention is related to a patterned membrane comprising nanofibrillar polysaccharides, device and compositions for improving wound healing, as well as to their manufacture and use for therapy.

Abstract: The invention provides a unique family of materials for use as OVDs in the course of eye treatment.